NEW HAVEN >> Alexion Pharmaceuticals will lay off 210 employees in the coming weeks as part of restructuring that a spokeswoman said is necessary to support the company’s long-term plans. The ...

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Alexion Pharmaceuticals stock hasn’t moved much this year. But that’s not new. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased less than 10% ...

What happened. Shares of Alexion Pharmaceuticals (NASDAQ: ALXN) , a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from ...

Image source: TBIT via pixabay. Alexion Pharmaceuticals' stock is off to a rough start for the year. The company's shares have traded right in lockstep with the biotech stock in general -- as ...

Investors in Alexion Pharmaceuticals, a biopharmaceutical company with a focus on rare diseases, received a double dose of good news earlier this week. The company just announced that European ...

In response to the company reporting expectation-topping first-quarter results and sharing upbeat pipeline news, shares of Alexion Pharmaceuticals (NASDAQ: ALXN) jumped 12% as of 3:15 p.m. EDT on ...